Effect of once-daily fluticasone furoate/vilanterol versus vilanterol alone on bone mineral density in patients with COPD: a randomized, controlled trial.

Saved in:
Bibliographic Details
Title: Effect of once-daily fluticasone furoate/vilanterol versus vilanterol alone on bone mineral density in patients with COPD: a randomized, controlled trial.
Authors: Maltais F; Centre de Recherche, Institut universitaire de cardiologie et de pneumologie de Québec, 2725 Chemin Sainte Foy, Québec City, QC, G1V 4G5, Canada., Schenkenberger I; Klinische Forschung Berlin GbR, Berlin, Germany., Wielders PLML; Department of Pulmonary Diseases, Catharina Hospital, Eindhoven, The Netherlands., Ortiz de Saracho J; Department of Pulmonary Diseases, El Bierzo Hospital, Ponferrada (León), Spain., Chinsky K; Chest Diseases of Northwestern PA, Erie, PA, USA., Watkins M; Respiratory Research and Development, GlaxoSmithKline plc., Research Triangle Park, NC, USA., Millar V; Biostatistics, GlaxoSmithKline plc., Uxbridge, UK., Crim C; Research and Development, GlaxoSmithKline plc., Research Triangle Park, NC, USA.
Source: Therapeutic advances in respiratory disease [Ther Adv Respir Dis] 2020 Jan-Dec; Vol. 14, pp. 1753466620965145.
Publication Type: Equivalence Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 101316317 Publication Model: Print Cited Medium: Internet ISSN: 1753-4666 (Electronic) Linking ISSN: 17534658 NLM ISO Abbreviation: Ther Adv Respir Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1753-4666
DOI:10.1177/1753466620965145